This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HIV/AIDS	HIV gp120; HIV gp41	Studies in patient samples and <i>in vitro</i> suggest the broadly neutralizing antibody (bNAb) 35O22 could help treat HIV. Screening of HIV-specific B cells in HIV-neutralizing patient serum and subsequent IgG cloning identified the bNAb 35O22 that neutralized sensitive HIV strains with a median IC ₅₀ value of 0.033 µg/mL. Structural studies showed that the bNAb bound to an epitope comprised of gp120 and gp41 residues distinct from those bound by other bNAbs that target the HIV spike protein. Next steps include evaluating 35O22 in combination with other bNAbs with complementary specificities.	Provisional patent application filed; available for licensing	Huang, J. <i>et al. Nature</i> ; published online Sept. 3, 2014; doi:10.1038/nature13601 Contact: Mark Connors, National Institutes of Health, Bethesda, Md. e-mail: mconnors@nih.gov
SciBX 7(37); doi:10.1038/scibx.2014.1102 Published online Sept. 25, 2014				